Research Summary

Research Subjects

• Identification of Alzheimer's risk control drug
• Genome abnormality verification technology
• Abnormality prediction technology for iPS cells and cells derived from iPS cells

Selected Publications

Papers with an asterisk(*) are based on research conducted outside of RIKEN.

• 1.*Imamura, K., Izumi, Y., Watanabe, A., Tsukita, K., Woltjen, K., Yamamoto, T., Hotta, A., Kondo, H., Kitaoka, S., Ohta, A., Tanaka, A., Watanabe, D., Morita, M., Takuma, H., Tamaoka, A., Kunath, T., Wray, S., Furuya, H., Era, T., Makioka, K., Okamoto, K., Fujisawa, T., Nishitoh, H., Homma, K., Ichijo, H., Julien, J., Obata, N., Hosokawa, M., Akiyama, H., Kaneko, S., Ayaki, T., Ito, H., Kaji, R., Takahashi, R., Yamanaka, S., Inoue, H.:
  “The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis,”
  Science Translational Medicine, 9(391), eaaf3962 ,2017.
• 2.*Shi, Y., Inoue, H., Wu, J. C., Yamanaka, S.:
  “Induced pluripotent stem cell technology: a decade of progress,”
  Nature Reviews Drug Discovery, 16, 115-130 (2017)
• 3.*Ohara, R., Imamura, K., Morii, F., Egawa, N., Tsukita, K., Enami, T., Shibukawa, R., Mizuno, T., Nakagawa, M., Inoue, H.: “Modeling drug-induced neuropathy using human iPSCs for predictive toxicology,”
  Clinical Pharmacology & Therapeutics, 101(6), 754-762,2017.
• 4.*Imamura, K., Sahara, N., Kanaan, N. M., Tsukita, K., Kondo, T., Kutoku, Y., Ohsawa, Y., Sunada, Y., Kawakami, K., Hotta, A., Yawata, S., Watanabe, D., Hasegawa, M., Trojanowski, J. Q., Lee, V. M., Suhara, T., Higuchi, M., Inoue, H.:
  “Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons,”
  Scientific Reports, 6, 34904,2016.
• 5.*Hanatani, T., and Takasu, N.:
  “iPS cell stock project,”
  BIO Clinica, 31(11), 18-22, 2016.
• 6.*Hanatani, T., and Takasu, N.:
  “Present and Future of an iPS Cell Stock for Regenerative Medicine,”
  Rinsho Byori, 65(2), 160-166,2017.

Related Links

Lab Members

Contact Information